Composition comprising elecampane extract for alleviating premenstrual syndrome symptom

Pending Publication Date: 2022-02-24
GENENCELL INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0026]The premenstrual syndrome extract contained as an active ingredient in the composition of the present invention has effects of significantly inhibiting the secretion of prolactin from the pituitary gland cells, increasing the secretion of progesterone in the luteal phase, and increasing the secretion of lowered luteinizing hormone and follicle-stimulating hormone. Therefore, the Aucklandiae radix extract can

Problems solved by technology

In particular, hormonal problems, such as a decrease in serotonin and an imbalance between progesterone and estrogen caused by an increase in prolactin, greatly affect the occurrence of premenstrual syndrome (Biggs and

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition comprising elecampane extract for alleviating premenstrual syndrome symptom
  • Composition comprising elecampane extract for alleviating premenstrual syndrome symptom
  • Composition comprising elecampane extract for alleviating premenstrual syndrome symptom

Examples

Experimental program
Comparison scheme
Effect test

examples 2 and 3

[0067]Aucklandiae radix extracts were prepared in the same manner as in Example 1, except that the concentration of ethanol during extraction was 50% (Example 2) or 70% (Example 3).

experimental example

Experimental Example 1: Measurement of Efficacy of Inhibition of Prolactin Secretion

[0069]The efficacy of inhibition of prolactin secretion by the Aucklandiae radix extracts obtained in Examples and Comparative Examples (Comparative Examples 1 to 3) were measured using pituitary cells.

[0070]Rat pituitary cells GH3 were purchased from the American Type Culture Collection (ATCC), DMEM culture medium, trypsin, and fetal bovine serum (FBS, Gibco™) were purchased from Invitrogen Corporation, and a prolactin ELISA kit for measurement was purchased from Mol-innovation.

[0071]GH3 pituitary cells were seeded at a concentration of 4×104 cells / well into a 24-well plate and incubated for 24 hours. In order to evaluate the efficacy of inhibition of prolactin secretion, the cells were treated with 25 and 50 μg / mL of the Aucklandiae radix extracts of Examples 1 to 3 and Comparative Examples 1 to 2 and then incubated for 48 hours, and prolactin secretion was assayed by application to a standard cur

experimental example 2

of Ameliorating Premenstrual Syndrome in Hyperprolactinemia-Induced Animal Model

[0074]Metoclopramide (MCP) is a substance used as a vomiting inhibitor and is known as a drug that increases the secretion of prolactin by inhibiting the secretion of dopamine, and thus inhibits the secretion of progesterone, luteinizing hormone, and follicle-stimulating hormone (Wang et al., 2014). Accordingly, in the present invention, an animal model with premenstrual syndrome induced by hormone secretion disorders was established by administering 20 mg / kg of metoclopramide into the abdominal cavity of female mice every two days for a total of 20 days and then inducing hyperprolactinemia.

[0075]ICR mice (female, 12 weeks old) were obtained from Raon Bio Co., Ltd. and were acclimated for 1 week while normal solid feed and water were freely supplied thereto. The environmental conditions of the rearing room were set to a temperature of 23±3° C., a relative humidity of 50±10%, an illumination time of 12 hou

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a composition comprising an elecampane extract for prevention and alleviation or treatment of premenstrual syndrome. In detail, the composition can be advantageously available as a composition for preventing, and alleviating or treating premenstrual syndrome in women, which effectively suppresses pituitary prolactin secretion, which is a phenomenon appearing in premenstrual syndrome, to increase the progesterone release amount lowered in the luteal phase of women as well as effectively controlling the decreased release of luteinizing hormone and follicle-stimulating hormone.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner GENENCELL INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products